FAS Wealth Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.65M	Buy	205,407 +3,000	+1%	+$28.8K	0.1%	143
2025 Q4	$2.36M	Buy	202,407 +1,787	+0.9%	+$17.4K	0.15%	118
2025 Q3	$2.02M	Buy	200,620 +51,460	+34%	+$739K	0.14%	126
2025 Q2	$2.6M	Buy	149,160 +9,625	+7%	+$139K	0.19%	103
2025 Q1	$1.76M	Buy	139,535 +44,830	+47%	+$539K	0.14%	119
2024 Q4	$999K	Buy	94,705 +9,850	+12%	+$138K	0.08%	147
2024 Q3	$1.23M	Buy	84,855 +17,199	+25%	+$205K	0.1%	136
2024 Q2	$576K	Buy	67,656 +7,186	+12%	+$63.8K	0.05%	187
2024 Q1	$618K	Buy	60,470 +14,500	+32%	+$108K	0.05%	180
2023 Q4	$252K	Hold	45,970	–	–	0.02%	266
2023 Q3	$174K	Buy	45,970 +11,720	+34%	+$76.9K	0.02%	279
2023 Q2	$229K	Buy	+34,250	New	+$229K	0.03%	242